TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: BPH impact index (BII)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Elimination of bacteria from hallux and toe sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Itching reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stinging and tightening reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LDL/HDL cholesterol ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: restenosis rates at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Affected hand score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AHA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced sense of competence of being a parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PaCO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleepiness improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Polysomnographic parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional and social functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chewing ability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective ratings of marijuana 'Strength'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WHOQOL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BFI
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Forearm blood flow (FBF) response to acetylcholine (ACh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral health knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Consensus between patients and professionals in items to retain
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Normalization of blood iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in urinary protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cornell depression scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median PEF (as percentage of run‐in best)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute psychotic symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary sinus blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary arterial diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parental anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comprehension-memorization scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic/diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual intimal hyperplasia area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target lesion revascularization (TLR) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent angina prompting urgent revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall antibiotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modern FP uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS decrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first SRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual incidence of SREs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSPA2 gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Thoughts of death or suicide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Moderate depression screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Early clinical response (≥20% reduction in infection area from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure rates at test-of-cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable microbiologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body CSE self-reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: anti-HDV prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MGALD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGAUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reocclusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevention of lower extremity injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage decline in albumin excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: regression to normoalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: progression to macroalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Survival benefit from greater dialysis doses
Endpoint domain: Mortality/survival
Primary endpoint: reduction in pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in speech recognition in background noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total PMSD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total PMTS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of repetitions completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure before exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total area under the plasma methylprednisolone concentration‐time curve (AUC 0‐‐infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half‐life (t1/2) of methylprednisolone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of methylprednisolone (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HGD/EAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: feasibility of self-administered acupressure for symptom management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment efficacy in lower respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Satisfactory serum drug concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine concentrations > 0.5 mg/dL at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Putrescine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Integral therapeutic efficacy rate of FAHT cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical effective rate of FAHT cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental measure efficacy of FAHT cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of regular soda
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of high-fat foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of fast-food restaurant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Median duration of oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median duration of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: End-of-day comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of prolactin-induced protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBTT (Satiation Before Total Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in the pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of stress urinary episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: arm fat index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting serum insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of GUD episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of HSV-2 associated GUD episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance to diagnostic investigations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance to treatment completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intradialytic events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of deep mycosis
Endpoint domain: Adverse events/effects
Primary endpoint: serum bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for mesh placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of haematoma formation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant complications
Endpoint domain: Adverse events/effects
Primary endpoint: Failure rate of ACL reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of symptom-free nights
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: serum lipid and lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-blood viscosity (WBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma viscosity (PV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin resistance development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: resting vaginal EMG assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: subjective outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NT-proBNP levels at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of night pain
Endpoint domain: Adverse events/effects
Primary endpoint: Complete symptom resolution (GDSS 0 or 1) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global symptomatic improvement at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pin site infection rate days per 1000 pin site days
Endpoint domain: Adverse events/effects
Primary endpoint: memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: memory interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: performance on interference word pair task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in shoulder/axillary pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of active muscle TrPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing sexual risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric insufflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Day 7 capillary piperaquine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3-4 chemotherapy-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Hourly plasma water iCa concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tCa mass balance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean minimum plasma potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum Q‐Tc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: spontaneously reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: TTE performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arousal level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical cutting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Morcellation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delivery <14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Preterm birth <37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H1 receptor occupancy (H1 RO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation and psychomotor performance
Endpoint domain: Adverse events/effects
Primary endpoint: combined post‐interventional neurological morbidity and mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine efficacy against first or only episode of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaccine efficacy against severe malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of P. falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Triceps skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gastrointestinal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Stability of DDK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary composite end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AZD3783 plasma concentration for 50% receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional integrity of visual sensorial pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ALBP score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 (bodily pain domain) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ-5D score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical antitumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle damage markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLQI (Dermatology Life Quality Index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Gram-negative bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate pain after laser surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Significant regrowth at week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in alpha current source density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean IOP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean PRNFL thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in telogen hair percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hair loss
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BMD percent changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision-making performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 2 or more oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: total parenteral nutrition (TPN) days
Endpoint domain: Adverse events/effects
Primary endpoint: Total urinary metal level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: myonuclear number in type II fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: satellite cells number in type II fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lean leg mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hypoglycemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Refractive error change after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' discomfort levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-efficacy for self-management of breast cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sweat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of left ventricular myocardial mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of target blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortisol response to naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive improvement as measured by the Positive and Negative Syndrome Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immune responses to vaccine antigens post-toddler dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of pyrexia and somnolence
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication of all treated baseline warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes